Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099049 | 0.82 | HDAC6 (0.41) | F2F10LOXL2ACHEMAOA | |
| SCHEMBL11886576 | 0.78 | MAOB (0.49) | MAOAMAOB | |
| SCHEMBL16376504 | 0.76 | CYP19A1 (0.53) | CYP19A1MAOA | |
| SCHEMBL123488 | 0.74 | CYP19A1 (0.51) | CYP19A1MAOB | |
| SCHEMBL123183 | 0.74 | CA12 (0.42) | F2F10LOXL2CYP19A1 | |
| SCHEMBL3617999 | 0.74 | APP (0.38) | F2F10LOXL2CYP19A1AGXT | |
| SCHEMBL119314 | 0.74 | CYP2A6 (0.51) | MAOAMAOB | |
| SCHEMBL18936000 | 0.72 | ACHE (0.36) | ACHEMAOAMAOB | |
| SCHEMBL9825775 | 0.71 | HDAC6 (0.35) | LOXL2ACHECYP19A1AGXTMAOA | |
| SCHEMBL119196 | 0.71 | LOXL2 (0.64) | LOXL2CYP19A1AGXTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1907384-A2 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007003961-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | GPR119, GCGR, GPR27 | F2 4031/4885F10 4119/4885LOXL2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.